Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.05 CAD
Change Today +0.005 / 12.50%
Volume 57.7K
MIR On Other Exchanges
As of 12:05 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

medmira inc (MIR) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/6/14 - C$0.09
52 Week Low
02/6/15 - C$0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDMIRA INC (MIR)

Related News

No related news articles were found.

medmira inc (MIR) Related Businessweek News

No Related Businessweek News Found

medmira inc (MIR) Details

MedMira Inc., a biotechnology company, engages in the research, development, manufacture, and sale of rapid diagnostics and technology platforms. Its research is focused on specific areas of the diagnostics market, including rapid, point-of-care, and in vitro sectors. Its products include Reveal HIV, which detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal HP/Rapid H. Pylori antibody tests that detect helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection; Reveal TP, a rapid syphilis antibody test, which detects treponema pallidum (TP) antibodies; Multiplo, a line of multiplex tests that combines testing solutions for HIV-1/2, Hepatitis B and C, and Syphilis in whole blood, serum, or plasma; and Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics. MedMira Inc. sells its rapid tests under the Reveal, Multiplo, and Miriad brands through a network of medical distributors and strategic business development partners with customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care facilities, governments, and public health agencies. The company sells and distributes its products in North America, Latin America and the Caribbean, Europe, the Asia Pacific, and the Middle East. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of Onsite Lab Holding AG.

Founded in 1993

medmira inc (MIR) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: C$188.0K
Chief Financial Officer
Total Annual Compensation: C$7.6K
Compensation as of Fiscal Year 2014.

medmira inc (MIR) Key Developments

MedMira Inc. Submits Reveal G4 Whole Blood Rapid HIV Test

MedMira Inc. has completed the submission of a supplement to their existing Premarket Approval for the United States Food and Drug Administration (FDA) approval of the next generation of its Reveal rapid HIV test. The supplement requests FDA approval of Reveal® G4 Rapid HIV-1 Antibody Test (Reveal G4), which adds the detection of HIV antibodies in fingerstick and venipuncture whole blood, to the product's current capabilities in testing serum and plasma specimens. Convenience care clinics where much of the HIV testing is taking place as healthcare providers implement the latest guidelines for routine screening. Built on MedMira's patented Rapid Vertical Flow Technology™ (RVF) platform, Reveal G4 offers point-of-care (POC) users a simple 3-step whole blood procedure which is completed in less than three minutes. The product will be sold in three distinct packaging formats, designed to meet the needs of a broad range of customers, including fingerstick whole blood (POC format), venipuncture whole blood/serum/plasma (LAB+ format), and serum/plasma (LAB S/P). MedMira has successfully served customers in hospitals and laboratories with a serum/plasma version of its Reveal rapid HIV test for the past decade. Reveal is routinely ranked as a top performer in these market sectors with the sensitivity and specificity as well as performance comparable to complex laboratory systems. The submission to the FDA is based on results from multi-center clinical trials conducted across the United States where Reveal G4 showed excellent results with fingerstick and whole blood specimens from a broad range of demographics. The additional whole blood capabilities of Reveal G4 will enable healthcare providers to better serve individuals 15-65 years of age and pregnant women seeking routine screening, helping to reduce the 50,000 new HIV infections in the US each year, including 100 to 200 babies born with HIV.

MedMira Inc. Reports Revenue Results for the Second Quarter Ended January 31, 2015

MedMira Inc. reported revenue results for the second quarter ended January 31, 2015. Revenues from product and service sales increased in the second quarter by 39% compared to the first quarter. The primary driver of this revenue growth was an increase in product revenue of 86% generated through sales made in the North America, Asia Pacific and Latin America. The company recorded revenue in the quarter totaling $722,502, which included product sales, related royalties, and service sales, as compared to $518,715 for the same period last year.

MedMira Inc. Reports Revenue Results for the First Quarter Ended October 31, 2014

MedMira Inc. reported revenue results for the first quarter ended October 31, 2014. For the quarter, the company recorded revenue in the quarter totaling $521,178, which included product sales, related royalties, and service sales, as compared to $472,846 for the same period last year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MIR:CN C$0.05 CAD +0.005

MIR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MIR.
View Industry Companies

Industry Analysis


Industry Average

Valuation MIR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDMIRA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at